Janssen, BMS Collaborate on Librexia, the Most Comprehensive FXIa Clinical Development Program

Janssen Pharmaceuticals and Bristol-Myers Squibb have collaborated to undertake the phase 3 Librexia program. Unrivaled as the most comprehensive oral factor XIa (FXIa) inhibitor clinical development program today, the program is investigating whether milvexian can enhance the benefit-risk profile associated with treating patients by delivering reduced thrombotic events with no increased risk of bleeding in acute coronary syndromes, stroke prevention in atrial fibrillation, and stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack.

At the American Heart Association’s Scientific Sessions 2023, DocWire News spoke with Jim List, MD, PhD, global therapeutic area head of cardiovascular and metabolism at Janssen Pharmaceuticals, and Puneet Mohan, MD, PhD, vice president and global program lead for milvexian at Bristol-Myers Squibb, about how this pivotal trial is leading the way within the broader FXIa landscape.